{"Immune": [0], "checkpoint": [1], "inhibitors": [2], "(ICIs)": [3], "have": [4, 129], "made": [5], "an": [6, 103], "indelible": [7], "mark": [8], "in": [9, 29, 122], "the": [10, 17, 54, 71, 80, 100, 123, 133, 175, 182], "field": [11], "of": [12, 19, 56, 60, 66, 73, 82, 99, 116, 180, 184], "cancer": [13, 61], "immunotherapy.": [14], "Starting": [15], "with": [16, 153, 196], "approval": [18, 52], "anti-cytotoxic": [20], "T": [21], "lymphocyte-associated": [22], "protein": [23], "4": [24], "(anti-CTLA-4)": [25], "for": [26, 53, 102, 135], "advanced-stage": [27], "melanoma": [28], "2011,": [30], "ICIs-which": [31], "now": [32], "also": [33], "include": [34], "antibodies": [35], "against": [36], "programmed": [37], "cell": [38, 193], "death": [39], "1": [40], "(PD-1)": [41], "and": [42, 49, 89, 105, 119, 138, 163, 177, 188, 190], "its": [43], "ligand": [44], "(PD-L1)-quickly": [45], "gained": [46], "US": [47], "Food": [48], "Drug": [50], "Administration": [51], "treatment": [55], "a": [57, 96], "wide": [58], "array": [59], "types,": [62], "demonstrating": [63], "unprecedented": [64], "extension": [65], "patient": [67], "survival.": [68], "However,": [69], "despite": [70], "success": [72], "ICIs,": [74, 181], "resistance": [75, 185], "to": [76, 85, 150, 160, 186], "these": [77, 144], "agents": [78], "restricts": [79], "number": [81], "patients": [83], "able": [84, 149], "achieve": [86, 161], "durable": [87, 165], "responses,": [88], "immune-related": [90], "adverse": [91], "events": [92], "complicate": [93], "treatment.": [94], "Thus,": [95], "better": [97], "understanding": [98], "requirements": [101], "effective": [104], "safe": [106], "antitumor": [107], "immune": [108, 124, 192], "response": [109], "following": [110, 126], "ICI": [111, 127], "therapy": [112, 128], "is": [113], "needed.": [114], "Studies": [115], "both": [117, 136], "tumoral": [118], "systemic": [120, 191], "changes": [121, 194], "system": [125], "yielded": [130], "insight": [131], "into": [132], "basis": [134], "efficacy": [137, 166], "resistance.": [139], "Ultimately,": [140], "by": [141], "building": [142], "on": [143], "insights,": [145], "researchers": [146], "should": [147], "be": [148], "combine": [151], "ICIs": [152], "other": [154], "agents,": [155], "or": [156], "design": [157], "new": [158], "immunotherapies,": [159], "broader": [162], "more": [164], "as": [167, 169], "well": [168], "greater": [170], "safety.": [171], "Here,": [172], "we": [173], "review": [174], "history": [176], "clinical": [178], "utility": [179], "mechanisms": [183], "therapy,": [187], "local": [189], "associated": [195], "outcome.": [197]}